Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
semaglutide
Pharma
The Oral GLP-1 Tracker: Oral Wegovy hits 3M prescription milestone
Fierce Pharma's weekly Oral GLP-1 Tracker monitors prescription trends for Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo.
Angus Liu
,
Kevin Dunleavy
,
Fraiser Kansteiner
Jun 8, 2026 4:00pm
ADA: Novo's Wegovy pill crosses hefty 3M prescription threshold
Jun 8, 2026 11:38am
Novo's Wegovy pill debuts with $355M in Q1
May 6, 2026 11:21am
Rybelsus brand retired in US as ‘Ozempic pill’ takes the stage
May 1, 2026 8:00am
Novo eyes adolescent diabetes approval for oral semaglutide
Apr 23, 2026 11:03am
UK cost watchdog clears Novo's Wegovy for cardio risk reduction
Apr 1, 2026 9:38am
